Cite
HARVARD Citation
Li, H. et al. (n.d.). 352 Efficacy and safety of abrocitinib in Chinese patients with moderate-to-severe atopic dermatitis: a post-hoc analysis of the JADE REGIMEN phase 3 trial. British journal of dermatology. p. . [Online].